Denali Therapeutics (NASDAQ:DNLI) Releases Earnings Results, Beats Expectations By $0.01 EPS

Denali Therapeutics (NASDAQ:DNLI) released its earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01, Briefing.com reports. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 13.50%. During the same quarter in the previous year, the company earned ($0.80) earnings per share.

Denali Therapeutics Trading Up 13.1 %

NASDAQ:DNLI traded up $2.20 during midday trading on Wednesday, hitting $19.05. 623,765 shares of the company were exchanged, compared to its average volume of 1,153,353. The company has a market capitalization of $2.72 billion, a PE ratio of -17.64 and a beta of 1.39. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.31. The company has a fifty day simple moving average of $18.82 and a 200 day simple moving average of $18.84.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DNLI shares. The Goldman Sachs Group decreased their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, February 29th. Wedbush reduced their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $95.00 price objective on shares of Denali Therapeutics in a research report on Wednesday. UBS Group dropped their price objective on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday, April 9th. Finally, Stifel Nicolaus dropped their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $40.22.

Insider Buying and Selling at Denali Therapeutics

In other news, insider Carole Ho sold 2,784 shares of Denali Therapeutics stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total value of $48,135.36. Following the sale, the insider now owns 145,010 shares of the company’s stock, valued at $2,507,222.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider Carole Ho sold 2,784 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $17.29, for a total transaction of $48,135.36. Following the sale, the insider now owns 145,010 shares of the company’s stock, valued at $2,507,222.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Steve E. Krognes sold 92,500 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the sale, the director now directly owns 47,341 shares in the company, valued at approximately $970,490.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 110,955 shares of company stock worth $2,218,802. 7.90% of the stock is owned by company insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.